At the same time, To overcome the physicochemical limitations of natural compounds and their undesirable pharmacokinetic properties such as poor absorption, distribution, metabolism, and excretion in vivo, the design and application of nanocarriers has attracted extensive attention leading to nanocarrier-based drug delivery systems
A typical starting dose may range between 500 mcg to 1500 mcg, administered daily or several times a week as advised by a healthcare professional
4613-C CLINICAL, GENETIC, AND PATHOLOGIC FEATURES, TREATMENT, AND LONG-TERM OUTCOME IN PATIENTS WITH BENIGN RECURRENT INTRAHEPATIC CHOLESTASIS: A MULTICENTER STUDY IN JAPAN Ken Kato 1 , Shuichiro Umetsu 2 , Takao Togawa 3 , Koichi Ito 3 , Takayoshi Kawabata 4 , Teruko Arinaga-Hino 1 , Naoya Tsumura 1 , Ryosuke Yasuda 1 , Yutaro Mihara 1 , Hironori Kusano 1 , Shogo Ito 3 , Kazuo Imagawa 5 , Hisamitsu Hayashi 6 , Ayano Inui 2 , Yushiro Yamashita 1 and Tatsuki Mizuochi 1 , (1)Kurume University School of Medicine, (2)Saiseikai Yokohamashi Tobu Hospital, (3)Nagoya City University Graduate School of Medical Sciences, (4)Ishikawa Prefectural Central Hospital, (5)University of Tsukuba, (6)The University of Tokyo Background: There have been few reports of benign recurrent intrahepatic cholestasis (BRIC) from East Asia
The patient was referred to our hospital because herpes encephalitis was suspected due to the acute onset of psychiatric symptoms
